Search This Blog

Thursday, September 2, 2021

Forte: Trial of FB-401 For the Treatment of Atopic Dermatitis Fails

 Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI).

Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active subjects achieving success compared to 29.5% in the placebo arm (p=0.2599). The primary endpoint of EASI-50 was achieved by 58% of subjects on FB-401 compared to 60% of subjects on placebo (p=0.7567).

"We are appreciative of the clinical trial sites and the patients for participating in this trial and we are grateful to our investors for taking the risk to support the advancement of a new therapeutic modality for atopic dermatitis," said Paul Wagner, Ph.D., CEO of Forte Biosciences. "The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401. We expect to provide investors with an update on the future plans for the company over the next several months."

https://finance.yahoo.com/news/clinical-trial-fb-401-treatment-200500416.html

Fauci: Covid vaccines likely need 3 shots for full regimen, instead of 2

 White House chief medical advisor Dr. Anthony Fauci said Thursday he would not be surprised if the recommended full regimen for the Pfizer and Moderna Covid-19 vaccines in the U.S. becomes three doses, instead of two.

Giving people an additional dose, or perhaps a final dose, several months after they’ve received their initial vaccination helps the immune system mature, said Fauci, also the director of the National Institute of Allergy and Infectious Diseases.

“I must say from my own experience as an immunologist, I would not at all be surprised that the adequate full regimen for vaccination will likely be three doses,” Fauci told reporters during a White House Covid briefing.

https://www.cnbc.com/2021/09/02/covid-vaccine-fauci-says-he-would-not-be-surprised-if-full-regimen-is-three-doses.html

COVID-19 vaccinations in rural areas hit fastest pace in 6 weeks

 Nearly 300,000 Americans in rural areas completed a COVID-19 vaccination series last week, translating to the largest weekly gain since mid-July, per data published by the nonprofit Center for Rural Strategies.

While rural counties logged about 150,000 weekly vaccinations by late July, the figure has since climbed to 292,898, according to the report. Also, the weekly number of residents in rural areas rolling their sleeves to receive a first dose increased by over two-thirds in the last three weeks and 39 of 47 states with rural counties saw an uptick in initial shots administered last week compared to two weeks prior. (Delaware, New Jersey and Rhode Island have no nonmetropolitan counties. Rural is defined as nonmetropolitan, according to the Office of Management and Budget MSA system.)

States with low vaccination rates appear to be gaining pace: Missouri was tied with the largest uptick in new vaccinations at 88 percent last week with almost 19,000 shots versus fewer than 10,000 two weeks ago. Alabama and Oklahoma were also among states with significant increases in new inoculations over the last week.

States with above-average vaccination rates are picking up vaccination rates too, according to the report which cites New Mexico and Hawaii, each with weekly vaccination rates climbing to 75 percent and 66 percent, respectively.

A reported 38.3 percent of the rural population is fully vaccinated against COVID-19, versus 49.1 percent in metropolitan areas, the nonprofit wrote. Massachusetts maintains the highest statewide rural vaccination rate at 69.4 percent, followed by Connecticut, Hawaii, Maine and New Hampshire. States with the lowest rural vaccination rates include Georgia, Virginia and West Virginia, per data sourced back to the Centers for Disease Control and Prevention (CDC). 

White House COVID-⁠19 Response Coordinator Jeff Zients on Tuesday also spoke to the increasing vaccination pace, citing an 80 percent increase since mid-July in the average number of daily vaccinations, climbing from about 500,000 to 900,000. Last week, the country logged over 6 million vaccinations, translating to the largest weekly total since July 5, Zients said.

The nationwide pace of first vaccinations has also accelerated, with over 14 million shots administered in August, or nearly 4 million more initial shots since July.

https://nypost.com/2021/09/02/covid-19-vaccinations-in-rural-areas-hit-fastest-pace-in-6-weeks/

OIG: Near half of Medicare beneficiaries hospitalized with COVID also treated for kidney, circulatory issues

 Medicare beneficiaries who were hospitalized with COVID-19 experienced a number of serious conditions, according to a new study.

The report, released this week by the Department of Health and Human Services' Office of Inspector General (OIG), says studying which conditions were linked most closely to severe COVID hospitalizations can be critical in helping the healthcare system prepare, especially as cases surge due to the delta variant.

Nearly all beneficiaries studied, about 55,000 across six cities, were treated for acute respiratory illness, according to the report. In addition, nearly half were treated for acute kidney failure, and close to half experienced acute circulatory issues.

The study found that one-third were treated for sepsis, and two-thirds were treated for notable endocrine, nutritional or metabolic issues.

"The complex needs of hospitalized Medicare beneficiaries—combined with surges in hospitalizations-may create substantial challenges in meeting the needs of these patients, particularly in light of the staffing and other problems that hospitals have reported," OIG researchers wrote in the report. 

"Gaining a better understanding of Medicare beneficiaries hospitalized with COVID-19—including the conditions for which they were being treated and demographic characteristics—can assist Federal, State, and local efforts in the COVID-19 pandemic and may be used to provide additional guidance to hospitals," the authors said.

The study found that more than half of the Medicare patients studied needed intensive care or mechanical ventilation. Black, Hispanic, dually eligible and older Medicare beneficiaries were disproportionately more likely to be hospitalized compared to other groups of beneficiaries, according to the study.

The researchers said the data can also be applied to enhance treatment of COVID-19.

https://www.fiercehealthcare.com/payer/oig-nearly-half-medicare-beneficiaries-hospitalized-covid-19-also-treated-for-kidney-failure

Healthcare-Associated Infections Spiked in 2020 in US Hospitals

 Several healthcare-associated infections in US hospitals spiked in 2020 compared to the previous year, according to a Centers for Disease Control and Prevention (CDC) analysis published September 2 in Infection Control and Hospital Epidemiology. Soaring hospitalization rates, sicker patients who required more frequent and intense care, and staffing and supply shortages caused by the COVID-19 pandemic are thought to have contributed to this increase.

This is the first increase in healthcare-associated infections since 2015.

These findings "are a reflection of the enormous stress that COVID has placed on our healthcare system," Arjun Srinivasan, MD (Capt, USPHS), the associate director of the CDC's Healthcare-Associated Infection Prevention Programs, in Atlanta, Georgia, told Medscape Medical News. He was not an author of the article, but he supervised the research. "We don't want anyone to read this report and think that it represents a failure of the individual provider or a failure of healthcare providers in this country in their care of COVID patients," he said. He noted that healthcare professionals have provided "tremendously good care to patients under extremely difficult circumstances.

People don't fail ― systems fail ― and that's what happened here," he said. "Our systems that we need to have in place to prevent healthcare-associated infection simply were not as strong as they needed to be to survive this challenge."

In the study, researchers used data reported to the National Healthcare Safety Network, the CDC's tracking system for healthcare-associated infections. The team compared national standard infection ratios — calculated by dividing the number of reported infections by the number of predicted infections — between 2019 and 2020 for six routinely tracked events:

  • central line-associated bloodstream infections

  • catheter-associated urinary tract infections (CAUTIs)

  • ventilator-associated events (VAEs)

  • infections associated with colon surgery and abdominal hysterectomy

  • Clostridioides difficile infections

  • methicillin-resistant Staphylococcus aureus (MRSA) infections

Infections were estimated using regression models created with baseline data from 2015.

"The new report highlights the need for healthcare facilities to strengthen their infection prevention programs and support them with adequate resources so that they can handle emerging threats to public health, while at the same time ensuring that gains made in combating HAIs [healthcare-associated infections] are not lost," said the Association for Professionals in Infection Control and Epidemiology in a statement.

The analysis revealed significant national increases in central line–associated bloodstream infections, CAUTIs, VAEs, and MRSA infections in 2020 compared to 2019. Among all infection types, the greatest increase was in central-line infections, which were 46% to 47% higher in the third quarter and fourth quarter (Q4) of 2020 relative to the same periods the previous year. VAEs rose by 45%, MRSA infections increased by 34%, and CAUTIs increased by 19% in Q4 of 2020 compared to 2019.

The influx of sicker patients in hospitals throughout 2020 led to more frequent and longer use of medical devices such as catheters and ventilators. The use of these devices increases risk for infection, David P. Calfee, MD, chief medical epidemiologist at the New York–Presbyterian/Weill Cornell Medical Center, in New York City, told Medscape. He is an editor of Infection Control and Hospital Epidemiology and was not involved with the study. Shortages in personal protective equipment and crowded intensive care units could also have affected how care was delivered, he said. These factors could have led to "reductions in the ability to provide some of the types of care that are needed to optimally reduce the risk of infection."

There was either no change or decreases in infections associated with colon surgery or abdominal hysterectomy, likely because there were fewer elective surgeries performed, said Srinivasan. C difficile–associated infections also decreased throughout 2020 compared to the previous year. Common practices to prevent the spread of COVID-19 in hospitals, such as environmental cleaning, use of personal protective equipment, and patient isolation, likely helped to curb the spread of C difficile. Although these mitigating procedures do help protect against MRSA infection, many other factors, notably, the use of medical devices such as ventilators and catheters, can increase the risk for MRSA infection, Srinivasan added.

Although more research is needed to identify the reasons for these spikes in infection, the findings help quantify the scope of these increases across the United States, Calfee said. The data allow hospitals and healthcare professionals to "look back at what we did and then think forward in terms of what we can do different in the future," he added, "so that these stresses to the system have less of an impact on how we are able to provide care."

Srinivasan and Calfee report no relevant financial relationships.

Infect Control Hosp Epidemiol. Published online September 2, 2021. Full text

https://www.medscape.com/viewarticle/958071

Physicians On the Long-COVID Front Lines

 Physical medicine and rehabilitation (PM&R) specialists have been on the front lines of treating the lingering effects of COVID-19 infection, so it's fitting that the specialty has started to roll out clinical guidance and tracking for "long COVID."

In August, the American Academy of Physical Medicine & Rehabilitation (AAPM&R) issued its first guidance on Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or long COVID, focusing on fatigue. The association has several other related guidances in the works from the organization's PASC Collaborative, with representation from PM&R, primary care and population health, and pulmonary and critical care.

AAPM&R also recently released a tracker that estimates PASC cases across the country to get a better handle on where resources, such as PASC treatment programs, may be needed most.

Steven Flanagan, MD, vice president of AAPM&R, answered questions from MedPage Today via email about the group's leadership role in PASC. Flanagan is also the chair of rehabilitation medicine at New York University Grossman School of Medicine and the medical director of Rusk Rehabilitation at NYU-Langone Health in New York City.

Following is an edited transcript of those questions and answers.

What do we know about PASC at this point in time?

Flanagan: According to two publications from JAMA, 10% to 30% of individuals who had COVID-19 reported at least one persistent symptom up to 6 months after the virus left their bodies. That means an estimated 3 to 10 million Americans are experiencing symptoms of long COVID.

These symptoms are varied and ongoing, and include neurological challenges, cognitive problems such as brain fog, shortness of breath, fatigue, musculoskeletal pain, and mobility issues.

At this point in time, research is ongoing to understand long COVID and recovery. AAPM&R's goal in creating a national call to action is to help long COVID patients reach their highest levels of recovery, and the dashboard we created illustrates the size and location of patients based on the best estimates for this population.

Given the size of this population and urgent needs, we are creating guidance statements based on multidisciplinary input to support comprehensive clinical treatment of patients with long COVID symptoms.

Tell us about the guidance focused on fatigue.

Flanagan: In March 2021, AAPM&R launched our multi-disciplinary PASC collaborative of experts, which consists of PM&R physicians and a diverse group of clinicians from across the U.S. with extensive experience leading COVID-19 recovery clinics.

PM&R physicians are leaders in directing rehabilitation and recovery, and we're medical experts in value-based evaluation, diagnosis, and management of neuromusculoskeletal and disabling conditions. This makes the field of PM&R uniquely qualified to help guide the multidisciplinary planning effort needed to address the rehabilitation and care needs of this rapidly growing patient population.

The goals of this collaborative are to create clinical guidance as well as education and resources to improve experience-of-care and health equity.

Throughout the summer, our collaborative, as well as patients and researchers living with long COVID, came together to create our fatigue guidance statement. In early August, we released this guidance in our PM&R Journal, which is the first in a series of peer-reviewed guidance statements to help physicians make clinical decisions concerning treatment of long COVID.

Fatigue is known to be one of the most common symptoms of long COVID that can significantly impact a patient's well-being and quality of life. Patients are often presenting with long-lasting and debilitating fatigue during their recovery, and while fatigue likely improves over time, it can persist beyond 6 months.

The pathophysiology causing fatigue after COVID-19 still warrants ongoing detailed research to better understand this constellation of symptoms, while acknowledging the cause of fatigue is likely multifactorial and may be specific to the individual.

Our guidance statement explains how to identify and diagnose fatigue in patients with PASC, analyze PASC fatigue presentation and assessment recommendations, differentiate and apply PASC fatigue treatment recommendations, identify health equity considerations and examples in PASC fatigue, as well as summarize the future directions in assessing and treating PASC-related fatigue.

As with any treatment plan, clinicians treating patients with PASC-related fatigue are encouraged to discuss the unknowns of PASC treatments, as well as the pros and cons of any therapeutic approach. The recommendations outlined in the guidance are based on the experience of the PASC Collaborative clinics and have helped to alleviate symptoms in cases in which specific contributing etiologies have not been identified or, despite being addressed, symptoms persist. As treatment efficacy of therapeutic options emerges, these recommendations will be reviewed and revised on a periodic basis.

As the Delta variant spreads, understanding how to identify and treat PASC-related fatigue is becoming more crucial. We're hopeful that this guidance will make a significant difference for patients with long COVID who are experiencing fatigue.

What additional PASC guidelines are in the works?

Flanagan: AAPM&R's multi-disciplinary PASC Collaborative has several long COVID guidance statements in the works, including cognitive impairment, breathing discomfort, cardiac and autonomic issues, neuropsychology, and pediatrics, which will be published on a rolling basis. Due to rapidly evolving knowledge on long COVID, these guidance statements will be reviewed and revised as new evidence emerges.

Along with guidance statement development, our collaborative is also focused on developing long COVID clinical infrastructure guidance. An estimated 80+ clinics have been created, and our Collaborative estimates that each can only handle 10 to 20 new patients per week, on average, compared to the millions of people who have symptoms.

The need for infrastructure guidance is critical to our Collaborative's goals and will support the Academy's overall call for a national plan, which emphasizes the need for research to advance the medical understanding of long COVID, equitable access to care for patients, and resources to build necessary infrastructure. The infrastructure needs to include resources to build necessary rehabilitation care infrastructure and funding to meet the crisis on national and local levels, as well as appropriate reimbursement for care.

Tell us about the decision to launch the PASC dashboard, and about the goals of the project.

Flanagan: It is crucial that we understand how many people have long COVID and where those populations are located to ensure we have the appropriate resources and infrastructure to support them, as well as equitable access to care, as prioritized in our call to action. Ultimately, our goal is to ensure that we, as a country, help long COVID patients reach their highest levels of recovery.

This is why we decided to launch our dashboard, which is the first of its kind that shows how many millions of Americans are estimated to be experiencing long COVID symptoms by state, county, and nationally.

The dashboard is based on data from Johns Hopkins University Center for Systems Science and Engineering (CSSE) COVID-19 data and the U.S. census, and includes state and county level statistics and trends over time. Our dashboard also has options for estimating the number of long COVID cases based on different assumptions and percentages.

It's such an important tool to help estimate and assess the growing population of people with long COVID to help hospitals, clinics, and healthcare professionals across the country prepare and plan for their care.

PASC has received more attention than any other post-viral illness. Will the focus on long COVID have implications for related illnesses, such as myalgic encephalomyelitis/chronic fatigue syndrome, as well?

In our fatigue guidance statement, we reiterate that long COVID includes individuals with many different types of fatigue and is a much broader definition without clear diagnostic criteria.

While certainly there are going to be some individuals with long COVID-related fatigue who go on to develop chronic fatigue syndrome, that percentage is unknown. We need more data to understand if and in which individuals long COVID-related fatigue is a manifestation of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and in which individuals long COVID-related fatigue represents a distinct process.

There are also lessons to be learned from past pandemics. Few people likely remember the history or impact of polio. The first polio epidemic in the U.S. occurred in 1895, but it was not until 1908 that the poliovirus was discovered. In the early 1900s, epidemics would regularly hit heavily populated cities during the summer. In the 1940s and 1950s, the disease killed or paralyzed about 500,000 people around the world every year.

PM&R physicians were instrumental in structuring comprehensive rehabilitation programs for polio survivors to help them advance their function and quality of life. Some of those patients are still being treated today by AAPM&R members.

At the start of the COVID pandemic last year, the media and health officials reminded us about the 1918 flu pandemic in which about 500 million people -- or one-third of the world's population at the time -- were infected. The number of deaths was estimated to be at least 50 million worldwide, with about 675,000 occurring in the U.S., according to the CDC.

There was also the 19th century Russian flu, which killed about 1 million people worldwide, out of a population of about 1.5 billion. Those who recovered from these infectious diseases suffered long-term health issues, and we weren't prepared to treat these patients as they continued their recovery. Had we been more aware of the history of these conditions, we'd be better prepared to deal with what we are facing now.

While we are still struggling to cope with COVID-19, the U.S. has surpassed 635,000 deaths from the disease. It is not too soon to remember and apply the lessons to long COVID that we should have learned from the pandemic. If we act now and create a comprehensive national crisis management plan, there is a chance we can avoid repeating the mistakes that helped create and prolong the coronavirus crisis.

https://www.medpagetoday.com/special-reports/exclusives/94334

Clover Health resumed at Neutral by Citi

 Target $10; previously Buy, target $19.

https://finviz.com/quote.ashx?t=CLOV